Evidence map›Paper›PMID 29293592›Full record

ArticlePloS one2018

Intravenously delivered mesenchymal stem cell-derived exosomes target M2-type macrophages in the injured spinal cord.

Karen L Lankford, Edgardo J Arroyo, Katarzyna Nazimek, Krzysztof Bryniarski, Philip W Askenase, Jeffery D Kocsis

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 128 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
128citing papers in PubMed, 1 pooled it
11.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

128 citing papers in PubMed, 1 synthesis or guideline pooled it, 231 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

68 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Karen L LankfordDepartment of Neurology, Yale University School of Medicine, New Haven, Connecticut, United States of America.
Edgardo J ArroyoDepartment of Neurology, Yale University School of Medicine, New Haven, Connecticut, United States of America.
Katarzyna NazimekDepartment of Immunology, Jagiellonian University College of Medicine, Krakow; Poland.
Krzysztof BryniarskiDepartment of Immunology, Jagiellonian University College of Medicine, Krakow; Poland.
Philip W AskenaseSection of Allergy and Clinical Immunology, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, United States of America.
Jeffery D KocsisDepartment of Neurology, Yale University School of Medicine, New Haven, Connecticut, United States of America.ORCID 0000-0002-3780-7719
Yale University · USJagiellonian University · PL

Funding

SOC CoreU54DA036134 · NIDA · BAYLOR COLLEGE OF MEDICINE · PI GALAS, DAVID J., GERSTEIN, MARK BENDER · 2013 to 2018
$15.0M
ALLERGY AND IMMUNOLOGY TRAINING GRANTT32AI007174 · NIAID · YALE UNIVERSITY · PI ASKENASE, PHILIP WILLIAM · 1985 to 2015
$2.6M
The Role of AID in Contact SensitivityR21AI076366 · NIAID · YALE UNIVERSITY · PI ASKENASE, PHILIP WILLIAM · 2009 to 2010
$636k
NIAID NIH HHS R21 AI076366NIAID NIH HHS T32 AI007174NIDA NIH HHS U54 DA036134NIH HHS 54 DA036134NIH HHS AI-07174NIH HHS AI-076366
6 · The paper itself

Abstract

In a previous report we showed that intravenous infusion of bone marrow-derived mesenchymal stem cells (MSCs) improved functional recovery after contusive spinal cord injury (SCI) in the non-immunosuppressed rat, although the MSCs themselves were not detected at the spinal cord injury (SCI) site [1]. Rather, the MSCs lodged transiently in the lungs for about two days post-infusion. Preliminary studies and a recent report [2] suggest that the effects of intravenous (IV) infusion of MSCs could be mimicked by IV infusion of exosomes isolated from conditioned media of MSC cultures (MSCexos). In this study, we assessed the possible mechanism of MSCexos action on SCI by investigating the tissue distribution and cellular targeting of DiR fluorescent labeled MSCexos at 3 hours and 24 hours after IV infusion in rats with SCI. The IV delivered MSCexos were detected in contused regions of the spinal cord, but not in the noninjured region of the spinal cord, and were also detected in the spleen, which was notably reduced in weight in the SCI rat, compared to control animals. DiR "hotspots" were specifically associated with CD206-expressing M2 macrophages in the spinal cord and this was confirmed by co-localization with anti-CD63 antibodies labeling a tetraspanin characteristically expressed on exosomes. Our findings that MSCexos specifically target M2-type macrophages at the site of SCI, support the idea that extracellular vesicles, released by MSCs, may mediate at least some of the therapeutic effects of IV MSC administration.

Indexed as

Cell TransplantationMesenchymal Stem CellsAnimalsCulture Media, ConditionedCulture Media, Serum-FreeExosomesMacrophagesOrgan SizeRatsRats, Sprague-DawleySpinal Cord InjuriesSpleenCulture Media, ConditionedCulture Media, Serum-Free

Identifiers

PMID29293592
PMCPMC5749801
OpenAlexW2782372577

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.